Want to see TNYA full AI Analyst Report?
Top Page
Tenaya Therapeutics
(NASDAQ:TNYA)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.37
▼(-47.00% Downside)
Action:Downgraded
Date:10/15/26
The score is pressured primarily by weak financial performance (large operating losses and continued negative free cash flow) and bearish technicals (below all key moving averages with negative momentum). Valuation offers little support because losses make the negative P/E hard to interpret and no dividend yield is available; the main positive factor is low balance-sheet leverage.
Positive Factors
Conservative leverage
Very low leverage limits fixed financial obligations and reduces near-term balance-sheet pressure while the company funds clinical development. This provides greater flexibility than a highly indebted structure, although ongoing losses still make capital preservation important over the next several quarters.
Negative Factors
Persistent operating losses
Large net and operating losses show that Tenaya remains far from sustainable profitability and continues to require substantial investment to advance its programs. Until clinical development produces meaningful commercial or partnering returns, these losses can constrain strategic flexibility and increase funding dependence.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative leverage
Very low leverage limits fixed financial obligations and reduces near-term balance-sheet pressure while the company funds clinical development. This provides greater flexibility than a highly indebted structure, although ongoing losses still make capital preservation important over the next several quarters.
Read all positive factors
Tenaya Therapeutics (TNYA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$87.23M
Dividend YieldN/A
Average Volume (3M)3.71M
Price to Earnings (P/E)―
Beta (1Y)3.01
Revenue GrowthN/A
EPS Growth45.08%
CountryUS
Employees70
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.53
Shares Outstanding224,230,010
10 Day Avg. Volume4,688,223
30 Day Avg. Volume3,710,006
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.88
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue64.92
Enterprise Value/Gross Profit24.62
Enterprise Value/Ebitda-0.90
Forecast
1Y Price Target
$13.00Price Target Upside1757.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$3.99M
Tenaya Therapeutics Business Overview & Revenue Model
Company Description
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associa...
Tenaya Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.52M | -8.44M | -8.47M | -8.69M | -8.71M | -4.03M |
| EBITDA | -95.96M | -82.16M | -102.66M | -115.40M | -117.20M | -69.76M |
| Net Income | -103.11M | -90.60M | -111.13M | -124.08M | -123.67M | -72.72M |
Balance Sheet | ||||||
| Total Assets | 93.54M | 146.92M | 119.94M | 170.51M | 278.94M | 316.65M |
| Cash, Cash Equivalents and Short-Term Investments | 78.08M | 100.55M | 61.45M | 104.64M | 186.53M | 251.30M |
| Total Debt | 3.95M | 10.83M | 13.61M | 12.42M | 15.10M | 15.70M |
| Total Liabilities | 24.13M | 23.66M | 27.09M | 31.09M | 35.57M | 38.12M |
| Stockholders Equity | 69.41M | 123.27M | 92.85M | 139.42M | 243.38M | 278.53M |
Cash Flow | ||||||
| Free Cash Flow | -71.83M | -68.88M | -91.53M | -103.31M | -125.05M | -85.93M |
| Operating Cash Flow | -71.56M | -68.26M | -90.50M | -102.07M | -104.42M | -60.81M |
| Investing Cash Flow | 8.61M | 56.08M | 1.13M | 48.72M | 83.65M | -238.56M |
| Financing Cash Flow | 58.70M | 108.41M | 47.75M | 4.05M | 77.77M | 208.97M |
Tenaya Therapeutics Technical Analysis
Negative
0.70
Price Trends
0.60
Negative
0.68
Negative
0.72
Negative
Market Momentum
-0.07
Positive
27.61
Positive
13.72
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNYA, the sentiment is Negative. The current price of 0.7 is above the 20-day moving average (MA) of 0.49, above the 50-day MA of 0.60, and below the 200-day MA of 0.72, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 27.61 is Positive, neither overbought nor oversold. The STOCH value of 13.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TNYA.
Tenaya Therapeutics Risk Analysis
Tenaya Therapeutics disclosed 67 risk factors in its most recent earnings report. Tenaya Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tenaya Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $614.44M | -5.70 | -89.38% | ― | ― | -108.75% | |
48 Neutral | $251.61M | -3.88 | -41.69% | ― | 6280.00% | -212.54% | |
46 Neutral | $321.71M | -7.47 | 21.48% | ― | ― | 33.25% | |
46 Neutral | $392.36M | -4.39 | -35.26% | ― | ― | -13.09% | |
42 Neutral | $107.22M | -0.96 | -57.92% | ― | -19.07% | 2.07% | |
40 Underperform | $87.23M | -0.73 | -108.05% | ― | ― | 45.08% |
* Healthcare Sector Average
TNYA
Tenaya Therapeutics
0.41
-1.25
-75.42%
GALT
Galectin Therapeutics
3.19
-1.91
-37.45%
ABEO
Abeona Therapeutics
4.31
-1.23
-22.20%
VYGR
Voyager Therapeutics
1.75
-3.06
-63.62%
TECX
Tectonic Therapeutic
19.95
1.33
7.14%
CADL
Candel Therapeutics
7.79
2.39
44.26%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.